Literature DB >> 9847366

Demonstration that orf2 encodes the feline immunodeficiency virus transactivating (Tat) protein and characterization of a unique gene product with partial rev activity.

A de Parseval1, J H Elder.   

Abstract

The long PCR technique was used to amplify the three size classes of viral mRNAs produced in cells infected by feline immunodeficiency virus (FIV). We identified in the env region a new splice acceptor site that generated two transcripts, each coding for an 11-kDa protein, p11(rev), whose function is unknown. The small-size class of mRNAs included two bicistronic orf2/rev mRNAs and two rev-like mRNAs, consisting only of the second exon of rev and coding for a 15-kDa protein, p15(rev). p15(rev) contained the minimal effector domain of Rev and was sufficient to mediate partial Rev activity. The bicistronic mRNAs encoded two distinct proteins, one of 23 kDa corresponding to Rev and a 9-kDa protein encoded by the orf2 gene. The orf2 gene product is a protein of 79 amino acids with characteristics similar to those of the Tat (transactivator) proteins of the ungulate lentiviruses. Transient expression assays, using the FIV long terminal repeat (LTR) to drive transcription of the bacterial gene for chloramphenicol acetyltransferase demonstrated that the orf2 gene transactivates gene expression an average of 14- to 20-fold above the basal level. Deletion mutants of the FIV LTR were generated to locate sequences responsive to transactivation mediated by the orf2 gene. A 5' deletion mutant that removed the AP1 site resulted in residual low-level transactivation by orf2. Further experiments using LTR mutants with internal deletions identified three regions located between positions -126 and -47 relative to the cap site that were important for orf2-directed transactivation. These regions include the AP1 site, a C/EBP tandem repeat, and an ATF site.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9847366      PMCID: PMC103867     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Comparison of two host cell range variants of feline immunodeficiency virus.

Authors:  T R Phillips; R L Talbott; C Lamont; S Muir; K Lovelace; J H Elder
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

2.  The open reading frame S of visna virus genome is a trans-activating gene.

Authors:  I Gourdou; V Mazarin; G Quérat; N Sauze; R Vigne
Journal:  Virology       Date:  1989-07       Impact factor: 3.616

3.  Characterization of a cDNA clone encoding the visna virus transactivating protein.

Authors:  J L Davis; J E Clements
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

4.  Identification of conserved and variable regions in the envelope glycoprotein sequences of two feline immunodeficiency viruses isolated in Zurich, Switzerland.

Authors:  S Morikawa; H Lutz; A Aubert; D H Bishop
Journal:  Virus Res       Date:  1991-09       Impact factor: 3.303

5.  A simple phase-extraction assay for chloramphenicol acyltransferase activity.

Authors:  B Seed; J Y Sheen
Journal:  Gene       Date:  1988-07-30       Impact factor: 3.688

6.  Sequences in the visna virus long terminal repeat that control transcriptional activity and respond to viral trans-activation: involvement of AP-1 sites in basal activity and trans-activation.

Authors:  J L Hess; J A Small; J E Clements
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

7.  Molecular cloning of a novel isolate of feline immunodeficiency virus biologically and genetically different from the original U.S. isolate.

Authors:  T Miyazawa; M Fukasawa; A Hasegawa; N Maki; K Ikuta; E Takahashi; M Hayami; T Mikami
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

8.  Molecular cloning of feline immunodeficiency virus.

Authors:  R A Olmsted; A K Barnes; J K Yamamoto; V M Hirsch; R H Purcell; P R Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

9.  Nucleotide sequence and genomic organization of feline immunodeficiency virus.

Authors:  R L Talbott; E E Sparger; K M Lovelace; W M Fitch; N C Pedersen; P A Luciw; J H Elder
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

10.  Interaction of a common cellular transcription factor, ATF, with regulatory elements in both E1a- and cyclic AMP-inducible promoters.

Authors:  Y S Lin; M R Green
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

View more
  33 in total

Review 1.  Human immunodeficiency virus and AIDS: insights from animal lentiviruses.

Authors:  R J Miller; J S Cairns; S Bridges; N Sarver
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

2.  Evolution of the long terminal repeat and accessory genes of feline immunodeficiency virus genomes from naturally infected cougars.

Authors:  Mary Poss; Howard Ross
Journal:  Virology       Date:  2007-09-29       Impact factor: 3.616

3.  Accessory genes confer a high replication rate to virulent feline immunodeficiency virus.

Authors:  Ryan M Troyer; Jesse Thompson; John H Elder; Sue VandeWoude
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

4.  Functional differences between human and bovine immunodeficiency virus Tat transcription factors.

Authors:  H P Bogerd; H L Wiegand; P D Bieniasz; B R Cullen
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

5.  Jembrana disease virus Tat can regulate human immunodeficiency virus (HIV) long terminal repeat-directed gene expression and can substitute for HIV Tat in viral replication.

Authors:  H Chen; J He; S Fong; G Wilcox; C Wood
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

Review 6.  Feline immunodeficiency virus (FIV) as a model for study of lentivirus infections: parallels with HIV.

Authors:  John H Elder; Ying-Chuan Lin; Elizabeth Fink; Chris K Grant
Journal:  Curr HIV Res       Date:  2010-01       Impact factor: 1.581

7.  Feline immunodeficiency virus envelope glycoproteins antagonize tetherin through a distinctive mechanism that requires virion incorporation.

Authors:  James H Morrison; Rebekah B Guevara; Adriana C Marcano; Dyana T Saenz; Hind J Fadel; Daniel K Rogstad; Eric M Poeschla
Journal:  J Virol       Date:  2014-01-03       Impact factor: 5.103

8.  Feline immunodeficiency virus OrfA is distinct from other lentivirus transactivators.

Authors:  Udayan Chatterji; Aymeric de Parseval; John H Elder
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 9.  Molecular mechanisms of FIV infection.

Authors:  John H Elder; Magnus Sundstrom; Sohela de Rozieres; Aymeric de Parseval; Chris K Grant; Ying-Chuan Lin
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

10.  Feline immunodeficiency virus ORF-Ais required for virus particle formation and virus infectivity.

Authors:  Malou C Gemeniano; Earl T Sawai; Christian M Leutenegger; Ellen E Sparger
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.